A new generation of
artificial heart valves
designed with:

  • Low Thrombogenicity*
  • Lifelong Durability*
  • Low Acoustic Signature*

Caution: Novostia technology is an investigational device not yet approved for sale

*as demonstrated during in-vitro and in-vivo studies


  • An answer to a large unmet need worldwide

  • For patients of any age, including children

  • Design for the aortic & mitral valves


 Patient benefits

"I have been impressed by the Triflo valve and look forward to starting  first-in-human clinical trials.

This valve has the potential to benefit thousands of patients each year, especially young people."

Prof. Thierry Carrel, M.D.
University Hospital of Zurich, Switzerland


Our key opinion leaders


This project has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No 947344

Horizon 2020




Swiss Medtech BioAlps Biopole  SPEI